• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Factor VIII, Fibrinogen and Heparin Resistance in COVID-19 Patients with Thromboembolism: How Should We Manage the Anticoagulation Therapy?

作者信息

Savioli Felicio, Claro Maurício, da Silva Ramos Fernando Jose, Pastore Laerte

机构信息

Critical Care Medicine Department, Hospital Sírio Libanês, Sao Paulo, Brazil.

出版信息

Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221087692. doi: 10.1177/10760296221087692.

DOI:10.1177/10760296221087692
PMID:35306858
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8938685/
Abstract
摘要

相似文献

1
Factor VIII, Fibrinogen and Heparin Resistance in COVID-19 Patients with Thromboembolism: How Should We Manage the Anticoagulation Therapy?新冠病毒肺炎血栓栓塞患者的凝血因子 VIII、纤维蛋白原与肝素抵抗：我们应如何管理抗凝治疗？
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221087692. doi: 10.1177/10760296221087692.
2
Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.住院 COVID-19 患者的凝血病：治疗性抗凝与标准治疗作为对 COVID-19 大流行的快速反应的实用随机对照试验 (RAPID COVID COAG - RAPID 试验)：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Mar 10;22(1):202. doi: 10.1186/s13063-021-05076-0.
3
Should we consider heparin prophylaxis in COVID-19 patients? a systematic review and meta-analysis.我们是否应该考虑对新冠肺炎患者进行肝素预防？一项系统评价和荟萃分析。
J Thromb Thrombolysis. 2021 Apr;51(3):830-832. doi: 10.1007/s11239-020-02253-x. Epub 2020 Aug 20.
4
Major hemorrhage and mortality in COVID-19 patients on therapeutic anticoagulation for venous thromboembolism.COVID-19 患者在接受抗凝治疗静脉血栓栓塞症时出现大出血和死亡。
J Thromb Thrombolysis. 2022 Oct;54(3):431-437. doi: 10.1007/s11239-022-02666-w. Epub 2022 Jun 10.
5
Coagulation, anticoagulation and pancreatic carcinoma.凝血、抗凝与胰腺癌
Nat Clin Pract Gastroenterol Hepatol. 2008 Aug;5(8):445-55. doi: 10.1038/ncpgasthep1184. Epub 2008 Jul 1.
6
How do palliative physicians manage venous thromboembolism?
Palliat Med. 1997 Nov;11(6):462-8. doi: 10.1177/026921639701100606.
7
Risk factors for systemic and venous thromboembolism, mortality and bleeding risks in 1125 patients with COVID-19: relationship with anticoagulation status.1125 例 COVID-19 患者的全身性和静脉血栓栓塞、死亡率和出血风险的危险因素：与抗凝状态的关系。
Aging (Albany NY). 2021 Mar 26;13(7):9225-9242. doi: 10.18632/aging.202769.
8
Effect of anticoagulation on the lysis of filter entrapped thromboembolism in dogs.
J Surg Res. 1985 Apr;38(4):391-9. doi: 10.1016/0022-4804(85)90053-8.
9
Heparin use during pregnancy.孕期使用肝素。
Tunis Med. 2002 Jun;80(6):297-305.
10
[Low-molecular-weight heparins].
Internist (Berl). 1998 Apr;39(4):414-5.

引用本文的文献

1
Heparin resistance management during cardiac surgery: a literature review and future directions.心脏手术期间肝素抵抗的管理：文献综述及未来方向。
J Extra Corpor Technol. 2024 Sep;56(3):136-144. doi: 10.1051/ject/2024015. Epub 2024 Sep 20.

本文引用的文献

1
Heparin Resistance - Clinical Perspectives and Management Strategies.肝素抵抗——临床观点与管理策略
N Engl J Med. 2021 Aug 26;385(9):826-832. doi: 10.1056/NEJMra2104091.
2
Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.重症监护病房中感染 SARS-CoV2 的患者的肝素剂量、水平和耐药性。
Int J Lab Hematol. 2021 Dec;43(6):1284-1290. doi: 10.1111/ijlh.13543. Epub 2021 Apr 14.
3
The coagulopathy, endotheliopathy, and vasculitis of COVID-19.COVID-19 的凝血功能障碍、血管内皮功能障碍和血管炎。
Inflamm Res. 2020 Dec;69(12):1181-1189. doi: 10.1007/s00011-020-01401-6. Epub 2020 Sep 12.
4
Differentiating biochemical from clinical heparin resistance in COVID-19.区分COVID-19中生化性与临床性肝素抵抗
J Thromb Thrombolysis. 2020 Nov;50(4):1015-1016. doi: 10.1007/s11239-020-02259-5.
5
Heparin resistance in COVID-19 patients in the intensive care unit.COVID-19 患者在重症监护病房中肝素耐药。
J Thromb Thrombolysis. 2020 Aug;50(2):287-291. doi: 10.1007/s11239-020-02145-0.
6
Extremely High Incidence of Lower Extremity Deep Venous Thrombosis in 48 Patients With Severe COVID-19 in Wuhan.武汉48例重症新型冠状病毒肺炎患者下肢深静脉血栓形成的极高发生率
Circulation. 2020 Jul 14;142(2):181-183. doi: 10.1161/CIRCULATIONAHA.120.047407. Epub 2020 May 15.
7
High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients.抗凝治疗的重症 COVID-19 患者中静脉血栓栓塞事件发生率高。
J Thromb Haemost. 2020 Jul;18(7):1743-1746. doi: 10.1111/jth.14869. Epub 2020 May 27.
8
Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2.感染新型冠状病毒（SARS-CoV-2）患者的血栓栓塞事件及明显的肝素抵抗
Int J Lab Hematol. 2020 Jun;42 Suppl 1(Suppl 1):19-20. doi: 10.1111/ijlh.13230.
9
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.异常的凝血参数与新型冠状病毒肺炎患者的预后不良有关。
J Thromb Haemost. 2020 Apr;18(4):844-847. doi: 10.1111/jth.14768. Epub 2020 Mar 13.
10
To be or not to be a case of heparin resistance.是否为肝素抵抗病例。
J Community Hosp Intern Med Perspect. 2018 Jun 12;8(3):145-148. doi: 10.1080/20009666.2018.1466599. eCollection 2018.